Skip to main content
SpringerLink
Log in

Analyse des recommandations du National Comprehensive Cancer Network portant sur les cancers du sein métastatiques V.1.2009

  • Chapter
Book cover Cancer du sein en situation métastatique

  • 216 Accesses

Résumé

Les recommandations du National Comprehensive Cancer Network (NCCN) reposent sur des niveaux d’évidence de catégories 2A ou autrement spécifiés. Le NCCN pense que la prise en charge optimale des patientes atteintes de cancer du sein est représentée par la participation dans des essais cliniques, ce qui est spécifiquement encouragé.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. The NCCN Clinical practice Guidelines in OncologyTM. Invasive Breast Cancer V.I.2009 www.NCCN.org

    Google Scholar 

  2. Bull JM, Tormey DC, Li SH et al. (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657

    Article  PubMed  CAS  Google Scholar 

  3. Hortobagyi GN, Gutterman JU, Blumenschein GR et al. (1979) Combination chemoimmunotherapy of metastatic breast cancer with 5 fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer 43: 1225–1233

    Article  PubMed  CAS  Google Scholar 

  4. Ackland SP, Anton A, Breitbach GP et al. (2001) Dose intensive epirubicin based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol 19: 943–953

    PubMed  CAS  Google Scholar 

  5. Langley RE, Carmichel J, Jones AL et al. (2005) Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclphosphamide as first line chemotherapy for metastatic breast cancer: United Kingdom Cancer Research Institute. J Clin Oncol 23: 8322–8330

    Article  PubMed  CAS  Google Scholar 

  6. Gianni L, Munzone E, Capri G et al. (1995) Paclitaxel by 3 hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose finding and sequence finding study. J Clin Oncol 13: 2688–2699

    PubMed  CAS  Google Scholar 

  7. Nabholtz J M, Falkson C, Campos D et al. (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer: results of a randomized,multicenter, phase III trial. J Clin Oncol 21: 968–975

    Article  PubMed  CAS  Google Scholar 

  8. Bonadonna G, Brusamolino E, Valagussa P et al. (1976) Combinaison chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410

    Article  PubMed  CAS  Google Scholar 

  9. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior survival with capecitabine plus docetaxel combinaison therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812–2823

    Article  PubMed  Google Scholar 

  10. Albain KS, Nag S et al. (2004) Global Phase III Study of Gemcitabine Plus Paclitaxel (GT) vs. Paclitaxel (T) as Frontline Therapy for Metastatic Breast Cancer (MBC); First Report of Overall Survival. J Clin Oncol 22(14S): 510

    Google Scholar 

  11. Chan S, Friedrichs K, Noel D et al. (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354

    PubMed  CAS  Google Scholar 

  12. Gundersen S, Kvinnsland S, Klepp O et al. (1986) Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol 22: 1431–1434

    Article  PubMed  CAS  Google Scholar 

  13. Bastholt L, Dalmark M, Gjedde SB et al. (1996) Dose response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish breast cancer coopertive group. J Clin Oncol 14: 1146–1155

    PubMed  CAS  Google Scholar 

  14. O’Brien ME, Wigler N, Inbar M et al. (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HC1 (CAELYX/Doxil) vs. Conventional doxorubicin for first line treatment of metastatic breast cancer. Ann Oncol 15: 440–449

    Article  PubMed  Google Scholar 

  15. Seidman A, Tiersten A, Hudis C et al. (1995) Phase II trial of paclitaxel by 3 hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575–2581

    PubMed  CAS  Google Scholar 

  16. Perez EA, Vogel CL, Irwin DH et al. (2001) Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer. J Clin Oncol 19: 4216–4223

    PubMed  CAS  Google Scholar 

  17. Burris HAR (1999) Single agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 26: 1–6

    PubMed  CAS  Google Scholar 

  18. Valero V (1997) Docetaxel as single agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24(Suppl 13): S11–S18

    Google Scholar 

  19. Burstein HJ, Manola J, Younger J et al. (2000) Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer. J Clin Oncol 18: 1212–1219

    PubMed  CAS  Google Scholar 

  20. Gradishar WJ, Tjulandin S, Davidson N et al. (2005) Phase III trial of Nanoparticle Albumin Bound Paclitaxel Compared With Polyethylated Castor Oil Based Paclitaxel in Women With Breast Cancer. J Clin Oncol 23: 7794–7803

    Article  PubMed  CAS  Google Scholar 

  21. Gradishar W, Krasnojon D, Cheporov S et al. (2007) Randomized comparison of weekly or every 3 week nab paclitaxel compared to q3w docetaxel as first line therapy in patients with metastatic breast cancer. J Clin Oncol 25: Abstract 1032

    Google Scholar 

  22. Bajetta E, Procopio G, Celio L et al. (2005) Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23: 2155–2161

    Article  PubMed  CAS  Google Scholar 

  23. Seidman AD (2001) Gemcitabine as single agent therapy in the management of advanced breast cancer. Oncology 15(Suppl 3): 11–14

    PubMed  CAS  Google Scholar 

  24. Zelek L, Barthier S, Riofrio M et al. (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92: 2267–2272

    Article  PubMed  CAS  Google Scholar 

  25. Miller K, wang M, Gralow J et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676

    Article  PubMed  CAS  Google Scholar 

  26. Robert N, Leyland Jones B, Asmar L, Belt R et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER 2 overexpressing metastatic breast cancer. J Clin Oncol 24: 2786–2279

    Article  PubMed  CAS  Google Scholar 

  27. Perez E (2004) Carboplatin in combination therapy for metastatic breast cancer. The Oncologist 9: 518–527

    Article  PubMed  CAS  Google Scholar 

  28. Slamon DJ, Leyland Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody agains HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  29. Seidman AD, Berry D, Cirrincione C et al. (2008) Randomized phase III trial of weekly compared with every 3 weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER 2 overexpressors and random assignment to trastuzumab or not in HER 2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26: 1642–1649

    Article  PubMed  CAS  Google Scholar 

  30. Marty M, Cognetti F, Marninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered as first line treastment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  31. Esteva FJ, Valero V, Booser D et al. (2002) Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER2 Overexpressing Metastatic Breast Cancer. J Clin Oncol 20: 1800–1808

    Article  PubMed  CAS  Google Scholar 

  32. Burstein HJ, Keshaviah A, Baron AD et al. (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2 overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110: 965–972

    Article  PubMed  CAS  Google Scholar 

  33. Bartch R, Wenzel C, Altorjai G et al. (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25: 3853–3858

    Article  Google Scholar 

  34. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus Capecitabine for HER2 Positive Advanced Breast Cancer. New Engl J Med 355: 2733–2743

    Article  PubMed  CAS  Google Scholar 

  35. Von Minckwitz G, Zielinski C et al. (2008) Capecitabine vs capecitabine + trastuzumab in patients with HER2 positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3 05). J Clin Oncol 26(suppl): Abstrast 1025

    Google Scholar 

  36. O’Shaughnessy J, Blackwell KL, Burstein H et al. (2008) A randomized study of lapatinib alone or in combinaison with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26(suppl): Abstract 1015

    Google Scholar 

  37. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational study of the efficacy and safety of humanized anti HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648

    PubMed  CAS  Google Scholar 

  38. Leyland Jones B, Gelmon K, Ayoub JB et al. (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combinaison with paclitaxel. J Clin Oncol 21: 3965–3971

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Jean Perrin, Rue Montalembert, 63000, Clermont-Ferrand

    J.-M. Nabholtz

Authors
  1. J.-M. Nabholtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag France

About this chapter

Cite this chapter

Nabholtz, JM. (2010). Analyse des recommandations du National Comprehensive Cancer Network portant sur les cancers du sein métastatiques V.1.2009. In: Cancer du sein en situation métastatique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0076-9_36

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0076-9_36

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0075-2

  • Online ISBN: 978-2-8178-0076-9

Publish with us

Policies and ethics

Search

Navigation